FindTrial
Sign In

ALK gene fragmentation detection kit (fluorescence in situ hybridization) clinical trial

ALK gene fragmentation detection kit (fluorescence in situ hybridization) clinical trial

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900021438
Enrollment
Unknown
Registered
2019-02-21
Start date
2019-02-18
Completion date
Unknown
Last updated
2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Gold Standard:Fluorescence in situ hybridization, immunohistochemistry, PCR amplification
Index test:Fluorescence&#32
in&#32
situ&#32
hybridization

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Non-small cell lung cancer patients with clinically diagnosed different pathological grades and disease duration are not limited in gender or age.

Exclusion criteria

Exclusion criteria: 1) Those whose core information is incomplete; 2) The tumor tissue sample used for testing does not meet the test requirements, such as: the number of cells in the tissue section is small, and the test requirements cannot be met.

Design outcomes

Primary

MeasureTime frame
ALK gene;—

Countries

China

Contacts

Public ContactWang Weiya

West China Hospital, Sichuan University

151422303@qq.com+86 13880766648

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026